The Association between Statin Use and Severe Outcomes in COVID-19 Infected Beneficiaries Enrolled in Mississippi Medicaid
Author(s)
Rong Y1, Pittman E2, Ramachandran S3, Bentley J3, Banahan III B4, Kirby T5, Smith D5, Bhattacharya K6
1University of Mississippi, Amherst, MA, USA, 2University of Mississippi, University, MS, USA, 3University of Mississippi, Oxford, MS, USA, 4Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 5Office of the Governor, Mississippi Division of Medicaid, Jackson, MS, USA, 6Center for Pharmaceutical Marketing and Management, University, MS, USA
Presentation Documents
Objective: Previous research suggests that the use of statin is associated with lower risk of severe outcomes among patients infected with the SARS-CoV-2 virus, but this has not been evaluated in a low-income Medicaid population. This study assessed the association between antecedent statin use and COVID-related hospitalization and all-cause death in Medicaid-enrolled patients with COVID-19. Methods: A retrospective cohort study was conducted using Mississippi Medicaid claims data from June 2019 to September 2021. Individuals between 18-64 years of age with a confirmed COVID-19 diagnosis (index date) were included. Continuous eligibility for 9 months pre-index through 3 months post-index period was required. Beneficiaries with antecedent statin use were identified based on records of statin prescription in the 90-day prior to the index date through pharmacy claims. Outcomes were all-cause mortality and hospitalization in 30 days, 60 days, and 90 days post index. Propensity score matching was performed to match statin users with non-users 1:1, based on age, sex, race, comorbidities, and medication use. Multivariable conditional logistic regression was conducted, adjusting for index month, cancer diagnosis and long-term care residency, to estimate the association of statin use with outcomes of interests. Results: A total of 10,792 beneficiaries met the inclusion criteria with 1,415 (13.1%) statin users. A total of 2,214 beneficiaries were included in the matched cohort. Unadjusted rates of COVID-related hospitalization and all-cause death in the matched cohort were 21.9% and 4.8% for statin users, and 21.5% and 7.4% for statin non-users, respectively. Multivariable logistic regression showed no significant difference in odds of hospitalization for matched statin users and non-users. Statin users have lower odds of mortality within 30 days (OR:0.51, 95%CI:0.32-0.83), 60 days (OR:0.56, 95%CI:0.37-0.85) and 90 days (OR:0.55, 95%CI:0.37-0.82) after diagnosis of COVID-19. Conclusion: COVID-19 beneficiaries with antecedent statin use might have lower odds of death after COVID infection.
Conference/Value in Health Info
2022-05, ISPOR 2022, Washington, DC, USA
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Acceptance Code
P60
Topic
Clinical Outcomes, Study Approaches
Topic Subcategory
Clinical Outcomes Assessment
Disease
Drugs, Respiratory-Related Disorders